ARFORMOTEROL TARTRATE
Arformoterol tartrate helps patients with chronic obstructive pulmonary disease (COPD), including those with chronic bronchitis and emphysema, manage long-term breathing issues. It is used twice daily as a maintenance therapy to address ongoing bronchoconstriction and is administered specifically through a nebulizer. This medication is intended for regular, morning and evening use rather than for treating sudden symptom flare-ups or asthma.
How ARFORMOTEROL TARTRATE Works
This drug works by stimulating beta 2-adrenergic receptors, which triggers an increase in intracellular cyclic AMP levels. This chemical change causes the smooth muscles in the bronchi to relax and inhibits the release of hypersensitivity mediators, such as histamine, from mast cells. These combined actions help keep the airways open and reduce the constriction associated with chronic lung disease.
Details
- Status
- Prescription
- First Approved
- 2021-06-22
- Routes
- INHALATION
- Dosage Forms
- SOLUTION
Companies
ARFORMOTEROL TARTRATE Approval History
What ARFORMOTEROL TARTRATE Treats
4 indicationsARFORMOTEROL TARTRATE is approved for 4 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Chronic Obstructive Pulmonary Disease
- Chronic Bronchitis
- Emphysema
- Bronchoconstriction
ARFORMOTEROL TARTRATE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to ARFORMOTEROL TARTRATE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT00754546 ARFEET results posted | 21261 | Ph 4 | completed | Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ARFORMOTEROL TARTRATE FDA Label Details
Indications & Usage
ARFORMOTEROL TARTRATE is indicated for the treatment of Chronic Obstructive Pulmonary Disease; Chronic Bronchitis; Emphysema; Bronchoconstriction.
Looking for the branded version?
BROVANA
Full clinical data, patents, trials, and competitive landscape for arformoterol tartrate.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.